BUTORPHANOL TARTRATE
Manufacturer: Hikma Pharmaceuticals USA Inc.
Score: 147.0
Butorphanol Tartrate Nasal Spray is an opioid analgesic used for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. It is a partial opioid agonist at the mu opioid receptor and a full agonist at the kappa opioid receptor. The drug has several key clinical findings and indications, including its use in postoperative pain, migraine headache pain, and pain of musculoskeletal origin. Important safety information includes the risk of addiction, abuse, and misuse, life-threatening respiratory depression, and neonatal opioid withdrawal syndrome. The main dosing recommendations include an initial dose of 1 mg, with titration to achieve adequate analgesia and minimize adverse reactions. Special population considerations include use in pregnancy, nursing mothers, pediatric patients, and geriatric patients, with caution advised due to increased sensitivity and potential for adverse reactions.
Addiction, abuse, and misuse; life-threatening respiratory depression; neonatal opioid withdrawal syndrome
Titrate dose based on individual patient response, with caution advised in elderly patients and those with hepatic or renal impairment
1 mg (1 spray in one nostril) every 3 to 4 hours as needed
Not recommended for use in patients below 18 years of age
OXYCODONE HYDROCHLORIDE ORAL SOLUTION
Aurolife Pharma, LLC
COCAINE HYDROCHLORIDE NASAL
OMNIVIUM PHARMACEUTICALS LLC.
MEPERIDINE HYDROCHLORIDE
Genus Lifesciences Inc.
BUPRENORPHINE
Bryant Ranch Prepack
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE
Bryant Ranch Prepack
OXYCODONE HYDROCHLORIDE
Bryant Ranch Prepack